View details of this raise on Seedstage

Monterey, CA

Developing a groundbreaking pain relief drug that eliminates the risk of addiction.

• Mission: Pioneering a first-in-class pain relief drug, N-001, that provides effective pain management without the risk of addiction, offering a safer alternative to traditional pain medications.  
• Innovation: Targets peripheral sensory neurons to disrupt pain signals, ensuring that the drug does not enter the brain, thereby eliminating the addiction risk associated with current pain management solutions.  
• Addiction Prevention: Focuses on delivering a non-addictive alternative to pain relief, directly addressing the opioid crisis by offering a safer option for individuals suffering from chronic or post-surgical pain.  
• Unique Manufacturing: Utilizes a distinctive drug delivery method involving bacterial proteins to target pain pathways, creating a competitive edge with a process that discourages imitation.  
• Efficacy and Safety: Backed by extensive in vitro and in vivo data, with a focus on both the efficacy of pain relief and patient safety, aiming to set a new standard in pain management.  
• Strategic Focus: Actively pursuing clinical testing and additional research to further develop N-001, positioning it as a revolutionary solution in the treatment of pain and addiction prevention.

Neurocarrus is pioneering a first-in-class sensory neuron specific pain drug, N-001, which aims to provide effective pain relief without the risk of addiction. The drug is designed to treat severe pain resulting from inflammation or surgical procedures, offering an alternative to traditional prescription medications that often come with unwanted side effects and addiction potential.

N-001 operates by targeting pain pathways while ensuring it does not enter the brain, thus eliminating the risk of addiction associated with many current pain management solutions. With a unique manufacturing process that discourages competition, Neurocarrus is positioned to revolutionize pain management and improve patient outcomes.

Backed by the National Institutes of Health, the company is on a trajectory to establish N-001 as the new standard of care in pain management, focusing on both efficacy and safety. This fundraising initiative aims to support the continued development and clinical testing of N-001, ultimately striving to enhance the quality of life for individuals suffering from chronic pain while addressing the critical issue of opioid addiction in healthcare.

Company Info

Neurocarrus develops novel drug delivery technologies to disrupt pain signals safely and effectively.

Neurocarrus is a biotechnology company focused on developing innovative drug delivery technologies aimed at safely disrupting pain signals without the risks associated with addiction or other systemic effects. The company’s primary product, N-001, is designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures. Neurocarrus targets peripheral sensory neurons, using bacterial proteins for targeted delivery to modify neuronal signaling. This approach aims to provide a non-addictive alternative to traditional pain management methods, addressing a significant unmet need in the healthcare market. The company has generated extensive in vitro and in vivo data supporting the efficacy of N-001 and is actively pursuing additional research and funding opportunities to further its development. Neurocarrus is headquartered in Monterey/Santa Cruz, California, and was founded by a team of prominent research scientists in the field of protein engineering. The company is positioned to play a significant role in the ongoing fight against the opioid crisis, which has severely impacted public health in the United States.